PharmaLytica 2021 Hyderabad review.

Alembic Pharma arm made agreement with Curon to develop cancer treatment drug in Greater China

On tuesday, drug firm Alembic Pharma declared that its associate company, Rhizen Pharmaceuticals, has entered an exclusive license agreement with Curon Biopharmaceutical for development and commercialisation of Tenalisib, used in treatment of cancer, in Greater China. Through its wholly owned subsidiary, Alembic Pharmaceuticals holds 50 percent ownership in Rhizen.

According to a regulatory filing, Rhizen Pharmaceuticals is a Switzerland-based privately held clinical-stage biopharmaceutical company, and Curon Biopharmaceutical is a clinical-stage innovative biopharmaceutical company with facility in Shanghai.

Alembic Pharma said in the filing: Under the terms of the agreement, Rhizen will receive an undisclosed upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of USD 149.5 million (approx Rs 1,047 crore) plus double-digit royalties on annual net sales of Tenalisib. Alembic Pharma said across all oncology indications, Curon obtains the exclusive development and commercialisation rights of Tenalisib for Greater China.

Later on, Alembic Pharma added, it will lead the clinical development in that territory by leveraging its expertise in translational research, clinical development and regulatory registration and its extensive research collaboration experience, to accelerate the development of and regulatory approval of this product in Greater China.


This Website Uses Cookies for Google Analytics, to improve your experience and to show you personalized advertising. By using this website you agree to our COOKIES AND PRIVACY POLICY...Learn More